Literature DB >> 32686043

Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed.

M P de Paula1, A B Moraes1, M das Graças Coelho de Souza2, E M R Cavalari1, R C Campbell1, G da Silva Fernandes1, M L F Farias1, L M C Mendonça3, M Madeira1, E Bouskela2, L G Kraemer-Aguiar2,4, L Vieira Neto5.   

Abstract

PURPOSE: Data on endothelial derangements in patients with non-functioning adrenal incidentaloma (NFAI) are scarce.
METHODS: We investigated if NFAI patients present clinical, biochemical and endothelial alterations compared to individuals without an adrenal lesion and also the associations among these variables. Forty-two NFAI and 40 controls were evaluated. NFAI diagnosis and controls were defined according to the current guidelines and based on a normal adrenal imaging exam, respectively. Body composition was evaluated by dual emission X-ray absorptiometry. Endothelial reactivity was assessed by two methods: tonometry (Endo-PAT®) and laser speckle contrast imaging (LSCI).
RESULTS: There were no differences between groups regarding age, gender, ethnicity, smoking status, and statin use. The frequency of metabolic syndrome according to the International Diabetes Federation criteria was 69% and 57.9%, respectively in NFAI and controls (p = 0.36), whereas the atherosclerotic cardiovascular disease (ASCVD) risk was 63.4% and 66.7% (p = 0.81). The clinical, laboratory, and anthropometric characteristics, as well as body composition, were similar between the groups. Additionally, any differences between groups were observed on endothelial reactivity tests. Nevertheless, we noted an association between cortisol levels after 1 mg-dexamethosone suppression test (1 mg-DST) and the duration of post-occlusive reactive hyperemia tested on microcirculation (r = 0.30; p = 0.03). NFAI patients require more antihypertensive drugs to achieve blood pressure control (p = 0.04). The number of antihypertensive drugs used to control blood pressure correlated with cortisol levels after 1 mg-DST (r = 0.29; p = 0.03).
CONCLUSIONS: Since both groups herein investigated had a high frequency of metabolic syndrome and ASCVD risk, it might explain similarities observed on endothelial reactivity. Nevertheless, prolonged reactive hyperemia response on microcirculation was correlated with cortisol levels under suppression.

Entities:  

Keywords:  Adrenal incidentaloma; Cardiovascular risk; Cytokines; Endothelial dysfunction; Nonfunctioning adrenal incidentaloma

Year:  2020        PMID: 32686043     DOI: 10.1007/s40618-020-01360-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

Review 1.  Adrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomes.

Authors:  Guido Di Dalmazi; Renato Pasquali
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

2.  Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio.

Authors:  C Nishida; G T Ko; S Kumanyika
Journal:  Eur J Clin Nutr       Date:  2009-11-25       Impact factor: 4.016

3.  Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.

Authors:  Ronen Rubinshtein; Jeffrey T Kuvin; Morgan Soffler; Ryan J Lennon; Shahar Lavi; Rebecca E Nelson; Geralyn M Pumper; Lilach O Lerman; Amir Lerman
Journal:  Eur Heart J       Date:  2010-02-24       Impact factor: 29.983

4.  [Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis].

Authors:  J A Divisón Garrote; M Seguí Díaz; C Escobar Cervantes
Journal:  Semergen       Date:  2014-08-05

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 6.  Adrenal incidentalomas and cardiometabolic morbidity: an emerging association with serious clinical implications.

Authors:  M Peppa; C Koliaki; S A Raptis
Journal:  J Intern Med       Date:  2010-10-22       Impact factor: 8.989

7.  Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events.

Authors:  Paul V Targonski; Piero O Bonetti; Geralyn M Pumper; Stuart T Higano; David R Holmes; Amir Lerman
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

8.  Long-term follow-up in adrenal incidentalomas: an Italian multicenter study.

Authors:  Valentina Morelli; Giuseppe Reimondo; Roberta Giordano; Silvia Della Casa; Caterina Policola; Serena Palmieri; Antonio S Salcuni; Alessia Dolci; Marco Mendola; Maura Arosio; Bruno Ambrosi; Alfredo Scillitani; Ezio Ghigo; Paolo Beck-Peccoz; Massimo Terzolo; Iacopo Chiodini
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

9.  Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.

Authors:  Anastasia S Mihailidou; Thi Yen Loan Le; Mahidi Mardini; John W Funder
Journal:  Hypertension       Date:  2009-10-19       Impact factor: 10.190

10.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

View more
  2 in total

1.  Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.

Authors:  Marta Araujo-Castro; Paola Parra Ramírez; Patricia Martín Rojas-Marcos; Rogelio García Centeno; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Miguel Antonio Sampedro Núñez; Cecilia Higueruela; Cristina Robles Lázaro
Journal:  Endocrine       Date:  2022-10-20       Impact factor: 3.925

2.  Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine?

Authors:  Iacopo Chiodini; Luigi Gennari
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-03       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.